| 发明名称 |
NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS |
| 摘要 |
The present invention is related to formulations containing a combination of dapoxetine or a pharmaceutically acceptable salt thereof with a phosphodiesterase Type 5 inhibitor or a pharmaceutically acceptable salt thereof. The invention is also related to a process for preparing a similar formulation and its use in treatment of erectile dysfunction. |
| 申请公布号 |
US2015216798(A1) |
申请公布日期 |
2015.08.06 |
| 申请号 |
US201314421292 |
申请日期 |
2013.08.13 |
| 申请人 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
发明人 |
Cifter Umit;Turkyilmaz Ali;Mutlu Onur |
| 分类号 |
A61K9/00;A61K31/4985;A61K31/506;A61K9/20;A61K31/519;A61K31/53;A61K31/137;A61K9/28 |
主分类号 |
A61K9/00 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. An orally disintegrating composition comprising, dapoxetine or a pharmaceutically acceptable salt thereof and a PDE5 inhibitor or a pharmaceutically acceptable salt thereof. |
| 地址 |
Istanbul TR |
